financetom
Business
financetom
/
Business
/
Nissan reduces output plan for new Leaf due to battery shortage, Nikkei says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Nissan reduces output plan for new Leaf due to battery shortage, Nikkei says
Sep 16, 2025 4:13 AM

TOKYO, Sept 16 (Reuters) - Nissan Motor ( NSANF ) has

reduced its production plan for the new model of its Leaf

electric vehicle by more than half for September-November owing

to delays in battery procurement, the Nikkei business daily said

on Tuesday.

Lower than expected battery yields at a Nissan ( NSANF ) affiliate had

caused the revision, the Nikkei said, adding that the Japanese

automaker planned to release the new EV model by the end of the

year.

The newspaper did not specify the original or revised

production targets but said that the output plan has been cut by

up to several thousand vehicles a month at its Tochigi plant in

eastern Japan, where the new version of the Leaf is made for the

U.S. and Japanese markets.

Nissan ( NSANF ) said it did not have any comment on speculative

reports, adding that the new model was progressing on schedule

towards its planned launch.

The company, which has gone from mass-market EV pioneer to

laggard since its first model entered showrooms in 2010, is

betting on the new version of its Leaf model to revive its

fortunes.

This is not the first time Nissan's ( NSANF ) EV production has hit a

snag. Another of Nissan's ( NSANF ) electric vehicles, the Ariya, was

hampered by problems at its high-tech production line at the

Tochigi plant in 2023, Reuters reported at the time.

Shares in Nissan ( NSANF ) closed 0.4% down before the Nikkei report,

underperforming a 0.3% gain for the benchmark Nikkei average

.

(Reporting by Daniel Leussink, Kiyoshi Takenaka and Satoshi

Sugiyama

Editing by Alex Richardson and David Goodman

)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
MNC Capital raises offer to acquire Vista Outdoor to over $3 billion
MNC Capital raises offer to acquire Vista Outdoor to over $3 billion
Jun 6, 2024
June 6 (Reuters) - Investment firm MNC Capital has raised its offer to acquire sporting and outdoor goods company Vista Outdoor ( VSTO ) to $39.50 per share, or over $3 billion, the investment firm said on Thursday. Shares of Vista Outdoor ( VSTO ) rose 8.4% to $37.34 in premarket trading. Vista Outdoor ( VSTO ) had rejected MNC...
Amazon Labor Union Agrees to Affiliate With Teamsters
Amazon Labor Union Agrees to Affiliate With Teamsters
Jun 6, 2024
06:50 AM EDT, 06/06/2024 (MT Newswires) -- Amazon.com's ( AMZN ) labor union has agreed to affiliate with the 1.3 million-member International Brotherhood of Teamsters. Amazon Labor Union members will vote to ratify the affiliation in the coming weeks. The Teamsters said its board unanimously approved the agreement. The union will represent the about 8,000 Amazon ( AMZN ) warehouse...
Boeing CEO Dave Calhoun to Testify Before US Senate Panel on June 18
Boeing CEO Dave Calhoun to Testify Before US Senate Panel on June 18
Jun 6, 2024
06:50 AM EDT, 06/06/2024 (MT Newswires) -- Boeing's ( BA ) chief executive officer, Dave Calhoun, will testify before a US Senate panel on June 18, Senator Richard Blumenthal, who chairs the permanent subcommittee on investigations, and senator Ron Johnson said in a statement late Wednesday. Blumenthal said Calhoun's testimony is a necessary step in meaningfully addressing Boeing's ( BA...
Seres to sell bacterial infection drug to Nestle Health for an undisclosed sum
Seres to sell bacterial infection drug to Nestle Health for an undisclosed sum
Jun 6, 2024
June 6 (Reuters) - Seres Therapeutics ( MCRB ) said on Thursday it has entered into a non-binding memorandum of understanding with Nestlé Health Science for the sale of its bacterial infection drug and related intellectual property rights. Under the terms of the pending agreement, Seres is due to receive capital infusions, including an undisclosed upfront payment. The U.S. Food...
Copyright 2023-2026 - www.financetom.com All Rights Reserved